All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
Extranodal natural killer (NK) T-cell lymphoma (ENKTL) is a rare and aggressive disease. Radiotherapy is effective in early-stage disease1, but most patients with advanced stage or extranasal disease have poor outcomes. This aggressive lymphoma is resistant to anthracycline-based chemotherapy2, and recent studies support the treatment with non-anthracycline-based chemoradiotherapy for localized disease3, and incorporating L-asparaginase into non-anthracycline -based regimens for advanced-stage and relapsed or refractory ENKTL.4-5
A recent study, published by Christopher Fox et al. in Lancet Haematology, analyzed data on a cohort of patients with ENKTL from the T-cell Project (NCT01142674), exploring the clinical characteristics and outcomes of patients with ENKTL.6
OS and PFS were estimated after a median follow-up of 44 months (IQR 20–61) and data are reported in Table 1.
CI, confidence interval; HR, hazard ratio; PFS, progression free survival; OS, overall survival | ||||||
Parameter |
Total ENKTL cohort |
Nasal type |
Extranasal type |
Stage I |
Stage II |
Stage III–IV |
---|---|---|---|---|---|---|
Median OS, months |
59 (95% CI, 41–86) |
not reached |
18 |
not reached |
29 |
10 |
HR 9.6 (95% CI, 9.2–32.4); p = 0.019 |
HR 3.1 (95% CI, 1–62); p = 0.067 |
vs stage I, HR 2.9 (95% CI, 2.4–16.1) |
||||
Median PFS, months |
20 (95% CI, 1–39) |
39 |
14 |
not reached |
13 |
8 |
HR 5.7 (95% CI, 5.1–28.9); p = 0.042 |
HR 3.2 (95% CI, 0–21); p = 0.012 |
vs stage I, HR 2.7 (95% CI, 2.1–14.2) |
||||
3-year OS, % |
|
63 |
44 |
69 |
48 |
33 |
3-year PFS, % |
|
51 |
39 |
|
|
|
5-year OS, % |
|
54 |
34 |
55 |
42 |
24 |
5-year PFS, % |
|
47 |
26 |
|
|
|
Based on PINK score, patients (n = 144 with available data) were classified as:
In low-risk vs intermediate-risk vs high-risk:
Outcomes based on treatment were evaluated in 130 patients (75 nasal disease, 55 extranasal) and data are reported in Table 2. The most used regimen incorporating L-asparaginase was the SMILE protocol (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide), administered in 23 patients.
PFS, progression free survival; OS, overall survival |
||||
Parameter |
Stage I–II |
Stage III–IV |
||
---|---|---|---|---|
Chemotherapy (n = 11) |
Chemotherapy plus radiotherapy (n = 48) |
Chemotherapy (n = 27) |
Chemotherapy plus radiotherapy (n = 27) |
|
3-year OS, % |
12 |
70 |
24 |
66 |
3-year PFS, % |
0 |
66 |
14 |
59 |
5-year OS, % |
12 |
59 |
24 |
58 |
5-year PFS, % |
0 |
53 |
0 |
40 |
Relative to the chemotherapeutic regimen used, outcomes in patients receiving L-asparaginase based regimen vs those receiving an anthracycline-based regimen vs those not receiving either drug, were:
Of 130 patients, 93 responded to first-line therapy:
In patients achieving CR, 5-year OS was 63% and 5-year PFS was 61%. In patients achieving only PR, 5-year OS was 32% and 5-year PFS was not estimable.
CR was also evaluated by treatment group:
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox